Daniel Treiber co-founded Recludix Pharma and currently serves as the Senior Vice President of Discovery Technology. Dr. Treiber is a drug discovery innovation leader, and over his 20+ year career he has invented and developed multiple disruptive and commercially successful platforms addressing unmet needs in the areas of family-wide screening and profiling (KINOMEscan®, BROMOscan®, BCL2scan™, E3scan™), cellular target engagement (InCELL Pulse™), and safety pharmacology (SAFETYscan47™). Prior to Recludix, Dr. Treiber served as Chief Technology Officer and Business Unit Site Head at Eurofins-DiscoverX and as Chief Technology Officer at DiscoverX. Dr. Treiber began his career at Ambit Biosciences, where he co-invented KINOMEscan and contributed to the discovery of the FLT3 kinase inhibitor Vanflyta (quizartinib). Vanflyta is approved for the treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukemia. Dr. Treiber was also a project team leader for multiple pre-clinical drug discovery programs that resulted in the nomination of the CSF1R inhibitor AC708 as a pre-clinical candidate. Dr. Treiber holds a Ph.D. from MIT and a B.A. from Middlebury College.
« Go Back